Literature DB >> 19755858

Inflammatory breast cancer cells are constitutively adapted to hypoxia.

Deborah Silvera1, Robert J Schneider.   

Abstract

We recently showed that overexpression of translation initiation factor eIF4G partially drives the unusual pathological features of Inflammatory Breast Cancer (IBC), the most lethal form of primary breast cancer. IBC has the peculiar feature that, rather than develop as a solid tumor, it typically generates rapidly metastasizing tight clusters of cancer cells referred to as tumor cell emboli, consisting of cancer cells held together by increased membrane expression of E-cadherin. Overexpression of eIF4GI in IBC leads to a specific increase in the translation of internal ribosomal entry site (IRES) containing mRNAs, of which two encode key proteins involved in the pathological features of IBC. One of these mRNAs encodes p120 catenin, which mediates E-cadherin retention at the cell surface, and the other encodes VEGF, which accounts for high levels of IBC angiogenesis and resistance to hypoxia. Here we show that IBC cells have adapted to the persistent hypoxia they experience as tumor emboli, by reprogramming the protein synthesis machinery to constitutively translate mRNAs required for IBC cell survival during hypoxia, even under normal oxygen (normoxic) conditions. Thus, IBC cells have been able to behave as if they are continuously hypoxic even when they are not.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19755858     DOI: 10.4161/cc.8.19.9637

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  24 in total

Review 1.  Translational control in cancer.

Authors:  Deborah Silvera; Silvia C Formenti; Robert J Schneider
Journal:  Nat Rev Cancer       Date:  2010-04       Impact factor: 60.716

Review 2.  Cellular IRES-mediated translation: the war of ITAFs in pathophysiological states.

Authors:  Anton A Komar; Maria Hatzoglou
Journal:  Cell Cycle       Date:  2011-01-15       Impact factor: 4.534

Review 3.  E-cadherin's dark side: possible role in tumor progression.

Authors:  Fausto J Rodriguez; Laura J Lewis-Tuffin; Panos Z Anastasiadis
Journal:  Biochim Biophys Acta       Date:  2012-03-13

4.  Mn porphyrin in combination with ascorbate acts as a pro-oxidant and mediates caspase-independent cancer cell death.

Authors:  Myron K Evans; Artak Tovmasyan; Ines Batinic-Haberle; Gayathri R Devi
Journal:  Free Radic Biol Med       Date:  2013-12-12       Impact factor: 7.376

5.  Inflammatory Breast Cancer Promotes Development of M2 Tumor-Associated Macrophages and Cancer Mesenchymal Cells through a Complex Chemokine Network.

Authors:  Amanda Valeta-Magara; Abhilash Gadi; Viviana Volta; Beth Walters; Rezina Arju; Shah Giashuddin; Hua Zhong; Robert J Schneider
Journal:  Cancer Res       Date:  2019-05-01       Impact factor: 12.701

6.  The proteome signature of the inflammatory breast cancer plasma membrane identifies novel molecular markers of disease.

Authors:  Ivette J Suárez-Arroyo; Yismeilin R Feliz-Mosquea; Juliana Pérez-Laspiur; Rezina Arju; Shah Giashuddin; Gerónimo Maldonado-Martínez; Luis A Cubano; Robert J Schneider; Michelle M Martínez-Montemayor
Journal:  Am J Cancer Res       Date:  2016-08-01       Impact factor: 6.166

7.  Equol, an isoflavone metabolite, regulates cancer cell viability and protein synthesis initiation via c-Myc and eIF4G.

Authors:  Columba de la Parra; Luis D Borrero-Garcia; Ailed Cruz-Collazo; Robert J Schneider; Suranganie Dharmawardhane
Journal:  J Biol Chem       Date:  2015-01-15       Impact factor: 5.157

Review 8.  Translational control in cancer etiology.

Authors:  Davide Ruggero
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-02-01       Impact factor: 10.005

9.  RhoC GTPase Is a Potent Regulator of Glutamine Metabolism and N-Acetylaspartate Production in Inflammatory Breast Cancer Cells.

Authors:  Michelle L Wynn; Joel A Yates; Charles R Evans; Lauren D Van Wassenhove; Zhi Fen Wu; Sydney Bridges; Liwei Bao; Chelsea Fournier; Sepideh Ashrafzadeh; Matthew J Merrins; Leslie S Satin; Santiago Schnell; Charles F Burant; Sofia D Merajver
Journal:  J Biol Chem       Date:  2016-04-25       Impact factor: 5.157

10.  Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.

Authors:  Komal Jhaveri; Eleonora Teplinsky; Deborah Silvera; Amanda Valeta-Magara; Rezina Arju; Shah Giashuddin; Yasmeen Sarfraz; Melissa Alexander; Farbod Darvishian; Paul H Levine; Salman Hashmi; Ladan Zolfaghari; Heather J Hoffman; Baljit Singh; Judith D Goldberg; Tsivia Hochman; Silvia Formenti; Francisco J Esteva; Meena S Moran; Robert J Schneider
Journal:  Clin Breast Cancer       Date:  2015-12-01       Impact factor: 3.225

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.